PRD Therapeutics
A biotech startup developing the world's first selective SOAT2 inhibitor oral drugs for rare and common lipid metabolism disorders.
Private Company
Estimated funding: $10M
AI Company Overview
A biotech startup developing the world's first selective SOAT2 inhibitor oral drugs for rare and common lipid metabolism disorders.
Technology Platform
Platform based on selective SOAT2 (Sterol O-acyltransferase 2) inhibitors, derived from the natural product pyripyropene A, representing the world's first and only selective SOAT2 inhibition approach.
Opportunities
Risk Factors
Competitive Landscape
PRD's primary differentiation is selectivity for SOAT2 over SOAT1, avoiding adverse events that doomed previous dual inhibitors; they compete against PCSK9 inhibitors, statins, and emerging MASH therapies from companies like Madrigal, 89bio, and Akero.